Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: Abbvie, Almirall, Ascletis, Biogen, Biomed, Eisai, Enochian, Eyenovia, Gain, Iaso, Imugene, Innovation, Krystal, Merck, Ovid, Passage, Periphagen, Scripps Research, University of Michigan.
Chinese state-owned enterprise China Meheco Group Co. Ltd. has signed a deal with Pfizer Inc. to be its mainland China partner for the commercialization of the COVID-19 pill Paxlovid (nirmatrelvir and ritonavir), which won conditional approval from China’s NMPA earlier this year.
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Bayer, Beigene, Hoth, Immunome, Oncternal, Orion, SGC Cell Therapy, Valneva.
Med-tech happenings, including deals and partnerships, grants, preclinical data and other news in brief: Audere, Medical Diagnostech, Nexstim, Royal Philips.
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Allogene, Antengene, Atyr, Immutep, In3bio, Intellia, Pharmazz, Quoin, Samsung Bioepis, Selecta, Servier, TG, Tracon.
Clinical updates, including trial initiations, enrollment status and data readouts and publications: Abbvie, Abivax, Amarin, Cocrystal, Confo, Excellthera, Gan & Lee, Geovax, Incannex, IQ-AI, Moderna, Passage, Pipeline, Redx, Transcenta, Venatorx.
Disagreement over offsets for an additional $15.6 billion in COVID-19 funding forced the supplemental pandemic funds recently requested by the White House to be cut from the fiscal 2022 spending bill, so the U.S. House would have the votes to pass the $1.5 trillion omnibus spending package late March 9.
RSS
